Oral and depot progestin therapy for endometriosis: towards a personalized medicine

References

• Vercellini P, Buggio L, Berlanda N, et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106:1552–1571.e2.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–275.
   PubMed Web of Science ®Google Scholar
• Ballard KD, Seaman HE, De Vries CS, et al. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study–Part 1. Bjog. 2008;115:1382–1391.
   PubMed Web of Science ®Google Scholar
• Howard FM. Endometriosis and mechanisms of pelvic pain. J Min Invas Gynecol. 2009;16:540–550.
   PubMed Web of Science ®Google Scholar
• Porpora MG, Koninckx PR, Piazze J, et al. Correlation between endometriosis and pelvic pain. J Am Assoc Gynecol Laparosc. 1999;6:429–434.
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927–935.
   PubMed Web of Science ®Google Scholar
• Gezer A, Oral E. Progestin therapy in endometriosis. Womens Health. 2015;11:643–652.
   Web of Science ®Google Scholar
• Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19:406–418.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Crosignani P, Somigliana E. The ‘incessant menstruation’ hypothesis: a mechanistic ovarian cancer model with implications for prevention. Hum Reprod. 2011;26:2262–2273.
   PubMed Web of Science ®Google Scholar
• Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107:533–536.
   PubMed Web of Science ®Google Scholar
• Berlanda N, Somigliana E, Vigano P, et al. Safety of medical treatments for endometriosis. Expert Opin Drug Saf. 2016;15:21–30.
   PubMed Web of Science ®Google Scholar
• Morotti M, Remorgida V, Venturini PL, et al. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol. 2014;179:63–68.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84:1375–1387.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Camerini G, Ragni N, et al. Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. Hum Reprod. 2010;25:94–100.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Consonni D, et al. Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod. 2012;27:3450–3459.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Frattaruolo MP, Somigliana E, et al. Surgical versus low-dose progestin treatment for endometriosis-associated severe deep dyspareunia II: effect on sexual functioning, psychological status and health-related quality of life. Hum Reprod. 2013;28:1221–1230.
   PubMed Web of Science ®Google Scholar
• Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007;92:2205–2207.
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci. 2012;19:563–571.
   PubMed Web of Science ®Google Scholar
• Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998;43:24–27.
   PubMedGoogle Scholar
• Kaser DJ, Missmer SA, Berry KF, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012;25:105–108.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril. 2016;105:734–743.e3.
   PubMed Web of Science ®Google Scholar
• Bizzarri N, Remorgida V, Leone Roberti Maggiore U. Dienogest in the treatment of endometriosis. Expert Opin Pharmacother. 2014;15:1889–1902.
   PubMed Web of Science ®Google Scholar
• Foster RH, Wilde MI. Dienogest. Drugs. 1998;56:825–833.
   PubMed Web of Science ®Google Scholar
• Lee DY, Lee JY, Seo JW, et al. Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis. Arch Gynecol Obstet. 2016;294:1257–1263.
   PubMed Web of Science ®Google Scholar
• Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35:1069–1076.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25:633–664.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Faustmann T, Gerlinger C, et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151:193–198.
   PubMed Web of Science ®Google Scholar
• Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002;77:684–692.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, doubleblind, multicenter, controlled trial. Fertil Steril. 2009;91:675–681.
   PubMed Web of Science ®Google Scholar
• Takaesu Y, Nishi H, Kojima J, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J Obstet Gynaecol Res. 2016;42:1152–1158.
   PubMed Web of Science ®Google Scholar
• Oh ST. The comparison between 2mg dienogest and high-dose medroxyprogesterone acetate on oral treatment of endometriosis. J Minim Invasive Gynecol. 2015;22:S170.
   PubMedGoogle Scholar
• Morotti M, Sozzi F, Remorgida V, et al. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol. 2014;183:188–192.
   PubMed Web of Science ®Google Scholar
• Leyland N, Casper R, Laberge P, et al. Medical management of pain associated with endometriosis. J Obstet Gynaecol Can. 2010;32:S9–S14.
   PubMedGoogle Scholar
• Caruso S, Iraci M, Cianci S. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. J Endocrinol Invest. 2015;38:1211–1218.
   PubMed Web of Science ®Google Scholar
• Angioni S, Nappi L, Pontis A. Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol. 2015;31:406–408.
   PubMed Web of Science ®Google Scholar
• Harada M, Osuga Y, Izumi G, et al. Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study. Gynecol Endocrinol. 2011;27:717–720.
   PubMed Web of Science ®Google Scholar
• Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, et al. Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017;211:108–111.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Faustmann T, Gerlinger C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health. 2015;7:393–401.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Christensen B, Henkel A, et al. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol. 2006;22:9–17.
   PubMed Web of Science ®Google Scholar
• Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci. 2003;997:163–173.
   PubMed Web of Science ®Google Scholar
• Collaborative Study Group on the desogestrel-containing progestogen-only pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 mcg/day or levonorgestrel 30 mcg/day. Eur J Contracept Reprod Health Care. 1998;3:169–178.
   PubMedGoogle Scholar
• Razzi S, Luisi S, Ferretti C, et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007;135:188–190.
   PubMed Web of Science ®Google Scholar
• Remorgida V, Abbamonte LH, Ragni N, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust N Z J Obstet Gynaecol. 2007;47:222–225.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93:239–247.
   PubMed Web of Science ®Google Scholar
• Morotti M, Remorgida V, Venturini PL, et al. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2014;183:178–182.
   PubMed Web of Science ®Google Scholar
• Moran C, Alcivia JC, Garcia-Hernandez E, et al. Treatment of endometriosis with cyproterone acetate. Preliminary Report. Arch Med Res. 1996;27:535–538.
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 602. Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123:1398–1402.
   PubMedGoogle Scholar
• Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. 1996;175:396–401.
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21:248–256.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85:314–325.
   PubMed Web of Science ®Google Scholar
• Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010;50:273–279.
   PubMed Web of Science ®Google Scholar
• Cundy T, Cornish J, Roberts H, et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 1998;92:569–573.
   PubMed Web of Science ®Google Scholar
• Scholes D, Lacroix AZ, Ott SM, et al. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93:233–238.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:475–582.
   Web of Science ®Google Scholar
• Scholes D, Lacroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–587.
   PubMed Web of Science ®Google Scholar
• Cromer BA. Bone mineral density in adolescent and young adult women on injectable or oral contraception. Curr Opin Obstet Gynecol. 2003;15:353–357.
   PubMed Web of Science ®Google Scholar
• Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. 2003;32:257–259.
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers MR, Nichols S, et al. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82:1580–1586.
   PubMed Web of Science ®Google Scholar
• Lara-Torre E, Edwards CP, Perlman S, et al. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17–21.
   PubMedGoogle Scholar
• Scholes D, Lacroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–144.
   PubMed Web of Science ®Google Scholar
• Modesto W, Bahamondes MV, Bahamondes L. Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive Depot medroxyprogesterone acetate. J Womens Health. 2015;24:636–640.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76.
   PubMed Web of Science ®Google Scholar
• Cromer BA, Bonny AE, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril. 2008;90:2060–2070.
   PubMed Web of Science ®Google Scholar
• Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception. 2010;81:281–291.
   PubMed Web of Science ®Google Scholar
• Food and Drugs Administration (FDA). 2004. Pfizer update information for Depo-provera. cited 2017 Feb 4; Available from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166395.pdf
   Google Scholar
• Health Canada Website. Health Canada Endorsed Important Safety Information on DEPO-PROVERA* (medroxyprogesterone acetate). cited 2017 Feb 4; Available from: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2004/14252a-eng.php
   Google Scholar
• Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80:7–17.
   PubMed Web of Science ®Google Scholar
• Veestegaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008;78:459–464.
   PubMed Web of Science ®Google Scholar
• Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab. 2010;95:4909–4916.
   PubMed Web of Science ®Google Scholar
• Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121:593–600.
   PubMed Web of Science ®Google Scholar
• D’Arcangues C. WHO statement on hormonal contraception and bone health. Contraception. 2006;73:443–444.
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Lähteenmäki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990;22:85–90.
   PubMed Web of Science ®Google Scholar
• Viganò P, Somigliana E, Vercellini P. Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: biological and clinical evidence. Womens Health. 2007;3:207–214.
   Google Scholar
• Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-realising IUD. Contraception. 1990;42:51–66.
   PubMed Web of Science ®Google Scholar
• Gomes MK, Rosa-e-Silva JC, Garcia CB, et al. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. Hum Reprod. 2009;24:2736–2745.
   PubMed Web of Science ®Google Scholar
• Engemise SL, Willets JM, Taylor HM, et al. Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system. Eur J Obestet Gynecol Reprod Biol. 2011;157:101–106.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 2001;75:485–488.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305–309.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20:1993–1998.
   PubMed Web of Science ®Google Scholar
• Ferreira RA, Vieira CS, Rosa-E-Silva JC, et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010;81:117–122.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95:492–496.
   PubMed Web of Science ®Google Scholar
• Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–526.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Hsu TF, Huang BS, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017;216:582.e1–582.e9.
   Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20:789–793.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Viganò P, et al. ‘Blood On The Tracks’ from corpora lutea to endometriomas. Bjog. 2009;116:366–371.
   PubMed Web of Science ®Google Scholar
• Kriplani A, Awasthi D, Kulshrestha V, et al. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynaecol Obstet. 2012;116:35–38.
   PubMed Web of Science ®Google Scholar
• Morelli M, Sacchinelli A, Ventturella R, et al. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gyneaecol Res. 2013;29:985–990.
   Web of Science ®Google Scholar
• Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand. 2014;93:38–44.
   PubMed Web of Science ®Google Scholar
• Kim ML, Cho YJ, Kim MK, et al. The efficacy of long-term maintenance therapy with a levonorgestrel-releasing intrauterine system for prevention of ovarian endometrioma recurrence. Int J Gynaecol Obstet. 2016;134:256–299.
   PubMed Web of Science ®Google Scholar
• McNicholas C, Maddipati R, Zhao Q, et al. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125:599–604.
   PubMed Web of Science ®Google Scholar
• Ali M, Akin A, Bahamondes L, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31:2491–2498.
   PubMed Web of Science ®Google Scholar
• Yisa SB, Okenwa AA, Husemeyer RP. Treatment of endometriotic catamenial haemoptysis with etonogestrel subdermal implant. Bjog. 2004;111:385–386.
   PubMed Web of Science ®Google Scholar
• Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care. 2005;31:67–70.
   PubMed Web of Science ®Google Scholar
• Al-Jefout M, Palmer J, Fraser IS. Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. Aust N Z J Obstet Gynaecol. 2007;47:247–249.
   PubMed Web of Science ®Google Scholar
• Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai. 2005;88(Suppl 2):S7–10.
   PubMedGoogle Scholar
• Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis–a pilot study. Contraception. 2009;79:29–34.
   PubMed Web of Science ®Google Scholar
• Beerthuizen R, Van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod. 2000;15:118–122.
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Monteiro-Dantas C, Espejo-Arce X, et al. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants. Hum Reprod. 2006;21:466–470.
   PubMed Web of Science ®Google Scholar
• Food and Drugs Administration (FDA). 2016. Implanon (etonogestrel) implants. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) cited 2017 Feb 5 Available from: https://www.fda.gov/safety/medwatch/safetyinformation/ucm400440.htm
   Google Scholar
• Agenzia Italiana del Farmaco AIFA, Nota Informativa Importante su Nexplanon (impianto contenente etonogestrel) (10/11/2016). cited 2017 Feb 6 Available from: http://www.aifa.gov.it/sites/default/files/DHPC_letter_Nexplanon_10.11.2016.pdf
   Google Scholar
• Alexander NJ, Baker E, Kaptein M, et al. Why consider vaginal drug administration? Fertil Steril. 2004;82:1–12.
   PubMed Web of Science ®Google Scholar
• Bedaiwy MA, Alfaraj S, Yong P, et al. New developments in the medical treatment of endometriosis. Fertil Steril. 2017;107:555–565.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Giudice LC, Evers JK, et al. Reducing low-value care in endometriosis between limited evidence and unresolved issues: a proposal. Hum Reprod. 2015;30:1996–2004.
   PubMed Web of Science ®Google Scholar
• Vercellini P. Endometriosis: the elusive gray area between evidence-based and evidence-biased medicine. Fertil Steril. 2014;101:45–46.
   PubMed Web of Science ®Google Scholar
• Brown J, Farquar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;3:CD009590.
   PubMed Web of Science ®Google Scholar